Loading organizations...

§ Private Profile · London, United Kingdom
Lindus Health is a technology company.
Lindus Health provides an all-in-one clinical research organization (CRO) solution, enabling life science companies to conduct radically faster and more reliable clinical trials. The company offers comprehensive CRO services, site operations, and an integrated technology platform that manages studies from protocol design through data delivery. Its approach leverages agile in-house technology for quicker study startups and utilizes access to electronic health records for efficient patient recruitment.
The company was founded in 2021 by Michael Young, Meri Beckwith, and Nik Haldimann. Their collective insight stemmed from the observed inefficiencies within the traditional clinical trial landscape, recognizing a need for a tech-first approach to streamline and accelerate the process. Meri Beckwith's background as a venture capital investor in digital health and biotechnology further informed their vision for a modernized CRO model.
Lindus Health primarily serves biotech and pharmaceutical companies seeking to accelerate the development of new treatments. Its mission centers on expediting clinical trials to bring novel therapies to patients sooner, fostering scientific innovation by making the research process more efficient and accessible. The company aims to redefine the standard for clinical research, offering a more responsive and effective partnership to its clients.
Lindus Health has raised $78.0M across 3 funding rounds.
Lindus Health has raised $78.0M in total across 3 funding rounds.
Lindus Health has raised $78.0M in total across 3 funding rounds.
Lindus Health's investors include Balderton Capital, Amino Collective, Creandum, EQT Ventures, Founders Fund, Presight Capital, TMV, Trevor Martin, Blockchange Ventures, Hummingbird Ventures, Multicoin Capital, Red Swan Ventures.
Lindus Health has raised $78.0M across 3 funding rounds. Most recently, it raised $55.0M Series B in January 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2025 | $55M Series B | Balderton Capital | Amino Collective, Creandum, EQT Ventures, Founders Fund, Presight Capital, TMV, Trevor Martin | Announced |
| Aug 1, 2023 | $18M Series A | Creandum | Amino Collective, Blockchange Ventures, EQT Ventures, Founders Fund, Hummingbird Ventures, Multicoin Capital, RED Swan Ventures, Serena Ventures, TMV, Adam Jackson, Julie Mcdermott | Announced |
| Nov 1, 2021 | $5M Seed | — | 500 Global, Alpha JWC Ventures, Amino Collective, Hummingbird Ventures, Presight Capital, White Star Capital, Dimiter Tschawow, Julie Mcdermott, Mato Peric | Announced |
Lindus Health is a technology-enabled clinical research organization (an “anti‑CRO”) that combines proprietary eClinical software, site operations, patient recruitment capabilities and full CRO services to run faster, more reliable clinical trials for biotech, device, diagnostics and consumer‑health sponsors[7][6]. Lindus emphasizes a performance‑aligned commercial model (fixed‑price, milestone payments), heavy use of electronic health records (EHRs) for recruitment, and an integrated tech + operations stack to shorten study timelines and improve enrollment and retention[7][1].
High‑Level Overview
For the product/company lens:
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Lindus Health is a well‑capitalized, tech‑first CRO alternative that combines software, EHR‑driven recruitment and multi‑modal site operations to speed clinical development; its continued impact will hinge on execution at scale, regulatory/ethical handling of EHR data, and measurable improvements in trial efficiency that sponsors can trust[7][3][5].